MTAP deficiency contributes to immune landscape remodelling and tumour evasion
Immunology · 2023-02 · 168 (2) · 331-345
DOI: 10.1111/imm.13587 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, online erschienen am 11.10.2022. Verfasst von Wen-Hsin Chang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, California, USA. Hauptthemen laut MEDLINE: B7-H1 Antigen, Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Methylthioadenosine phosphorylase (MTAP) deficiency occurs in various malignancies and is associated with poor survival in cancer patients. However, the mechanisms underlying tumour progression due to MTAP loss are yet to be elucidated. Utilizing integrated analyses of the transcriptome, proteome and secretome, we demonstrated that MTAP deficiency alters tumour‐intrinsic, immune‐related pathways and reprograms cytokine profiles towards a tumour‐favourable environment. Additionally, MTAP‐knockout cells exhibited a marked increase in the immune checkpoint protein PD‐L1. Upon co‐culturing primary T cells with cancer cells, MTAP loss‐mediated PD‐L1 upregulation inhibited T cell‐mediated killing activity and induced several T cell exhaustion markers. In two xenograft tumour models, we showed a modest increase in average volume of tumours derived from MTAP‐deficient cells than that of MTAP‐proficient tumours. Surprisingly, a remarkable increase in tumour size was observed in humanized mice bearing MTAP‐deficient tumours, as compared to their MTAP‐expressing counterparts. Following immunophenotypic characterization of tumour‐infiltrating leukocytes by mass cytometry analysis, MTAP‐deficient tumours were found to display decreased immune infiltrates with lower proportions of both T lymphocytes and natural killer cells and higher proportions of immunosuppressive cells as compared to MTAP‐expressing tumour xenografts. Taken together, our results suggest that MTAP deficiency restructures the tumour immune microenvironment, promoting tumour progression and immune evasion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of California, Davis, Davis, California, USA.
- Division of Nephrology, Department of Internal Medicine, University of California, Davis, Davis, California, USA.
- Comprehensive Cancer Center, University of California, Davis, Davis, California, USA.
- Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, Davis, California, USA.
- Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
ORCID-Profile: Wen-Hsin Chang, Ching-Hsien Chen
Förderung
- NCI NIH HHS
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
- U.S. Department of Defense
Zitieren
APA
Chang, W. H., Hsu, S. W., Zhang, J., Li, J. M., Yang, D. D., Chu, C. W., Yoo, E. E., Zhang, W., Yu, S. L., & Chen, C. H. (2023). MTAP deficiency contributes to immune landscape remodelling and tumour evasion. Immunology, 168(2), 331-345. https://doi.org/10.1111/imm.13587
Vancouver
Chang WH, Hsu SW, Zhang J, Li JM, Yang DD, Chu CW, et al. MTAP deficiency contributes to immune landscape remodelling and tumour evasion. Immunology. 2023;168(2):331-345. doi:10.1111/imm.13587
BibTeX
@article{Chang2023,
author = {Chang, Wen-Hsin and Hsu, Ssu-Wei and Zhang, Jun and Li, Ji-Min and Yang, David D and Chu, Chih-Wei and Yoo, Estelle E and Zhang, Weici and Yu, Sung-Liang and Chen, Ching-Hsien},
title = {MTAP deficiency contributes to immune landscape remodelling and tumour evasion},
journal = {Immunology},
year = {2023},
volume = {168},
number = {2},
pages = {331--345},
doi = {10.1111/imm.13587}
}
EUVIMED